No hay productos en el carrito



Antiplatelet Therapy in Acs and A-Fib (Advances in Cardiology, Vol. 47)
Serebruany, V. — Atar, D.
1ª Edición Septiembre 2012
Inglés
Tapa dura
170 pags
300 gr
null x null x null cm
ISBN 9783318021684
Editorial KARGER
LIBRO IMPRESO
-5%
122,22 €116,11 €IVA incluido
117,52 €111,64 €IVA no incluido
Recíbelo en un plazo de
2 - 3 semanas
Description
Written by top experts in the field
Platelets play a critical role in the pathophysiology of acute coronary syndromes (ACS) and thromboembolic complications associated with atrial fibrillation. Anticoagulant and antiplatelet therapies are central to the treatment of ACS and atrial fibrillation. Over the last several decades, a better understanding of the pathogenesis of coronary heart disease and atrial fibrillation has led to refinements in antithrombotic strategies and clinical outcomes.
With this in mind, some of the issues outlined in this book are new insights in genetic testing and modification of individualized antiplatelet therapy based on rapid bedside platelet analyzers. Most importantly, the current update of pros and cons of novel antiplatelet agents such as prasugrel and ticagrelor are provided in detail. Conventional antiplatelet strategies with aspirin and clopidogrel are also discussed. Special attention is devoted to experimental antiplatelet agents like PAR-1 thrombin receptor antagonists or aptamers.
The ability to focus on different diseases beyond ACS, including heart failure and atrial fibrillation, distinguishes this publication. Each chapter was written by top experts in the field and scientists with the utmost authority and expertise to provide cardiologists, internists, and clinical pharmacologists with the latest updates.
© 2025 Axón Librería S.L.
2.149.0